Description

Sofosbuvir and Velpatasvir Tablets 100 mg combines two direct-acting antiviral (DAA) agents that target different stages of the hepatitis C virus life cycle. This pan-genotypic therapy is widely used for effective and well-tolerated treatment of chronic HCV infection.

🔬 Mechanism of Action

• Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor that blocks viral RNA replication.
• Velpatasvir is an NS5A inhibitor that interferes with viral replication and assembly.

Together, they prevent the virus from multiplying and spreading, leading to viral clearance from the bloodstream.

💊 Indications

Sofosbuvir and Velpatasvir Tablets are indicated for:

• Chronic Hepatitis C Virus (HCV) infection (Genotypes 1–6)
• Patients with or without compensated cirrhosis
• Certain cases of decompensated cirrhosis (in combination with ribavirin, as prescribed)

📌 Key Features of Sofosbuvir and Velpatasvir Tablets 100 mg

• Strength: 100 mg (combination formulation strength may vary by brand)
• Dosage Form: Oral tablet
• Therapeutic Class: Direct-Acting Antiviral (DAA)
• Administration: Taken orally once daily, with or without food
• Treatment Duration: Typically 12 weeks (as prescribed)
• Monitoring: Liver function tests and viral load (HCV RNA) monitoring required

⚕️ Benefits of Sofosbuvir and Velpatasvir Tablets 100 mg

• Pan-genotypic coverage (effective against all major HCV genotypes)
• High cure rates (SVR >95% in many cases)
• Well-tolerated oral therapy
• Short treatment duration

⚠️ Precautions

• Risk of hepatitis B virus (HBV) reactivation — screening recommended before therapy
• Use caution in patients with severe liver impairment
• Potential drug interactions with certain medications (e.g., amiodarone)
• Use under physician supervision

Sofosbuvir and Velpatasvir Tablets 100 mg offers a highly effective, pan-genotypic treatment option for chronic hepatitis C infection, providing high cure rates and improved long-term liver health when administered under medical guidance.